Par Health Unveils First Generic Version of Janumet® XR in the U.S.
In a significant advancement for diabetes treatment accessibility, Par Health, Inc. has officially launched the first FDA-approved generic version of Janumet® XR in the United States. This launch follows the company's receipt of approval for its Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA). The generic medication combines sitagliptin and metformin HCl in an extended-release tablet format for effective management of type 2 diabetes.
Janumet® XR, originally developed and marketed by Merck, has been a critical player in the diabetes treatment space, boasting estimated annual sales of around $269.9 million in the U.S. according to IQVIA data from May 2026. Par Health's successful introduction of this generic drug underscores its commitment to providing affordable healthcare solutions for patients requiring diabetes treatment.
Jake Longenecker, Executive Vice President and Chief Commercial Officer of Par Health, announced the launch, expressing pride in being the first to market with a generic version. He stated, "This milestone not only enhances our generics portfolio but also reflects our ongoing mission to deliver quality, low-cost medicines to improve patient access and outcomes."
The launch of Par Health's sitagliptin metformin XR marks a pivotal moment in the pharmaceutical landscape, especially for patients in need of diabetes medications. With only one FDA-approved generic available, competition within the market can lead to lowered prices and improved availability, ultimately benefiting patients and healthcare providers alike.
This development is part of Par Health's larger strategy to elevate essential medicines, focusing on quality and affordability. The company operates a robust manufacturing network and extensive distribution capabilities, positioning it to meet the growing demand for generic medications in various therapeutic areas.
Healthcare professionals and patients are encouraged to stay informed about the benefits and potential side effects associated with the use of sitagliptin metformin XR. Additional details and prescribing information can be found on Par Health’s official website or through their customer service contacts.
Par Health continues to navigate the challenges of the pharmaceutical industry, including competition, regulatory landscape, and supply chain dynamics, while striving to maintain standards of compliance and quality across its product offerings. As they expand their generics range, Par Health remains committed to being at the forefront of pharmaceutical innovation, ensuring that essential medications are accessible and affordable for all.
In summary, the introduction of the first generic version of Janumet® XR by Par Health is not just a business achievement; it's a step forward in improving healthcare access for patients struggling to manage their diabetes. As Par Health continues to innovate and expand, it reaffirms the importance of competitive pricing and availability in the ever-evolving pharmaceutical market, fostering a healthier future for all individuals reliant on such medications.
Janumet® XR, originally developed and marketed by Merck, has been a critical player in the diabetes treatment space, boasting estimated annual sales of around $269.9 million in the U.S. according to IQVIA data from May 2026. Par Health's successful introduction of this generic drug underscores its commitment to providing affordable healthcare solutions for patients requiring diabetes treatment.
Jake Longenecker, Executive Vice President and Chief Commercial Officer of Par Health, announced the launch, expressing pride in being the first to market with a generic version. He stated, "This milestone not only enhances our generics portfolio but also reflects our ongoing mission to deliver quality, low-cost medicines to improve patient access and outcomes."
The launch of Par Health's sitagliptin metformin XR marks a pivotal moment in the pharmaceutical landscape, especially for patients in need of diabetes medications. With only one FDA-approved generic available, competition within the market can lead to lowered prices and improved availability, ultimately benefiting patients and healthcare providers alike.
This development is part of Par Health's larger strategy to elevate essential medicines, focusing on quality and affordability. The company operates a robust manufacturing network and extensive distribution capabilities, positioning it to meet the growing demand for generic medications in various therapeutic areas.
Healthcare professionals and patients are encouraged to stay informed about the benefits and potential side effects associated with the use of sitagliptin metformin XR. Additional details and prescribing information can be found on Par Health’s official website or through their customer service contacts.
Par Health continues to navigate the challenges of the pharmaceutical industry, including competition, regulatory landscape, and supply chain dynamics, while striving to maintain standards of compliance and quality across its product offerings. As they expand their generics range, Par Health remains committed to being at the forefront of pharmaceutical innovation, ensuring that essential medications are accessible and affordable for all.
In summary, the introduction of the first generic version of Janumet® XR by Par Health is not just a business achievement; it's a step forward in improving healthcare access for patients struggling to manage their diabetes. As Par Health continues to innovate and expand, it reaffirms the importance of competitive pricing and availability in the ever-evolving pharmaceutical market, fostering a healthier future for all individuals reliant on such medications.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.